Marksans Pharma eyes European growth as Goa capacity ramp-up supports volumes

Investment View

Axis Securities, in its August 31, 2026 Axis PUNCH report on Marksans Pharma Ltd, recommends BUY with a target price of Rs 362 per share, implying 10 per cent upside from the CMP of Rs 330. The report has a medium-term investment horizon of three to six months and views Marksans Pharma as positioned to benefit from structural growth in regulated global healthcare markets.

European Expansion and Product Diversification

The broker's central thesis is based on targeted European acquisitions and front-end expansion. Marksans Pharma has acquired Netherlands-based QliniQ B.V. and Germany-based ABCnow GmbH, while also establishing operating entities in Ireland and Germany.

Axis Securities believes these initiatives broaden the product portfolio beyond store-brand over-the-counter products into higher-margin prescription formulations in regulated European markets. Management is targeting Rs 1,000 crore of European revenue over the next three to five years. The report also identifies front-end market entries in Germany, Ireland and Canada as supportive of the growth opportunity.

Capacity Expansion and Product Pipeline

Capacity expansion is a second key driver. Marksans Pharma is ramping up the acquired Teva Goa manufacturing facility, which the broker expects to improve operating efficiency, create operating leverage and support volume scale-up.

The company has global formulation capacity of 26 billion units annually across four accredited facilities in India, the US and the UK. Its research and development pipeline comprises over 200 products under development and more than 350 approved ANDAs and MAs. Axis Securities expects this product platform, along with 15 to 20 annual launches, to support market-share gains across North America, the UK, Europe and Australasia.

Management Targets and Strategic Vision FY30

Management has guided for 15 to 20 per cent revenue growth in FY27 and revenue of Rs 4,000 crore within two years. Under its Strategic Vision FY30, management aims to double revenue to Rs 6,000 crore while maintaining EBITDA margins of 20 to 22 per cent.

Management expects commissioning of new formulation lines and commercialisation of recent acquisitions to accelerate volumes. It is also pursuing adjacent dosage forms, including soft gels and liquids, while retaining a debt-free balance sheet and disciplined return expectations.

Marksans Pharma had net cash of Rs 1,058 crore, which Axis Securities views as financial capacity for calibrated inorganic expansion. Management is targeting ROCE and ROE above 18 to 20 per cent.

Business Profile and Financial Outlook

The report describes Marksans Pharma's business across OTC drugs, prescription formulations, branded generics and contract manufacturing. Consolidated financial summary figures and Axis Securities' estimates are presented below:

Recommendation Rationale and Key Risks

The BUY recommendation is supported by the following factors:

• European expansion.
• Goa capacity ramp-up.
• The research and development pipeline.
• An expanding store-brand OTC presence.
• Diversification into branded prescription generics.
• Net cash exceeding Rs 1,000 crore.

The report does not state a separate valuation methodology beyond this growth and operating-leverage rationale.

Key risks include delays in product approvals or capacity ramp-up, and price fluctuations in key raw materials and solvents.